KPTI - Karyopharm: What's Next After The Briefing Document For Selinexor?
The correct attitude of the security analyst toward the stock market might well be that of a man toward his wife. He shouldn’t pay too much attention to what the lady says, but he can’t afford to ignore it entirely. That is pretty much the position that most of us find ourselves vis-Ã -vis the stock market. - Benjamin Graham (The Father of Value Investing)
On Feb. 22, 2019, Karyopharm (NASDAQ:KPTI) shares tumbled over 43% as the briefing document for the February 26 Oncologic Drugs Advisory Committee ("ODAC") was released. The information pertaining to